HTG Molecular Diagnostics Performance
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
The company retains a Market Volatility (i.e., Beta) of -0.99, which attests to possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning HTG Molecular are expected to decrease slowly. On the other hand, during market turmoil, HTG Molecular is expected to outperform it slightly. HTG Molecular Diagnostics currently retains a risk of 0.0%. Please check out HTG Molecular maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if HTG Molecular will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days HTG Molecular Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, HTG Molecular is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 9.6 M | |
| Free Cash Flow | -18.4 M |
HTG |
HTG Molecular Relative Risk vs. Return Landscape
If you would invest 57.00 in HTG Molecular Diagnostics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding HTG Molecular Diagnostics or generate 0.0% return on investment over 90 days. HTG Molecular Diagnostics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than HTG, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
HTG Molecular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HTG Molecular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HTG Molecular Diagnostics, and traders can use it to determine the average amount a HTG Molecular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| HTGM |
Based on monthly moving average HTG Molecular is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HTG Molecular by adding HTG Molecular to a well-diversified portfolio.
HTG Molecular Fundamentals Growth
HTG Stock prices reflect investors' perceptions of the future prospects and financial health of HTG Molecular, and HTG Molecular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HTG Stock performance.
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| EBITDA | (20.14 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Earnings Per Share | (17.10) X | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
About HTG Molecular Performance
By examining HTG Molecular's fundamental ratios, stakeholders can obtain critical insights into HTG Molecular's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that HTG Molecular is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. Htg Molecular operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.Things to note about HTG Molecular Diagnostics performance evaluation
Checking the ongoing alerts about HTG Molecular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HTG Molecular Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HTG Molecular is not yet fully synchronised with the market data | |
| HTG Molecular has some characteristics of a very speculative penny stock | |
| HTG Molecular has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.37 M. Net Loss for the year was (21.59 M) with loss before overhead, payroll, taxes, and interest of (2.01 M). | |
| HTG Molecular Diagnostics currently holds about 14.1 M in cash with (18.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing HTG Molecular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HTG Molecular's stock is overvalued or undervalued compared to its peers.
- Examining HTG Molecular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HTG Molecular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HTG Molecular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HTG Molecular's stock. These opinions can provide insight into HTG Molecular's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |